Skip to main content
Log in

Changes in Hemostasis System in Outbred Female Mice with Cisplatin-Induced Procoagulant Status

  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

Procoagulant status was modeled in outbred female mice by single injection of cisplatin in a maximum tolerated dose and hemostasis parameters monitored over 30 days by methods of coagulogram and low-frequency piezothromboelastography (global test). Monitoring revealed waveform changes in the hemostatic potential: the structural and chronometric hypercoagulation recorded starting from the first day and attaining its maximum on days 5-7 was followed by hypocoagulation and returned to normocoagulation on day 30. This pattern reflects prolonged effect of cisplatin: formation of severe dysfunction of the endothelium providing the main anticoagulant pool of hemostasis (day 1) aggravated by disturbances of the plastic functions of the liver (days 15-20), and recovery (days 20-30).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Abdol Razak NB, Jones G, Bhandari M, Berndt M. C, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018;10(10). pii: E380. https://doi.org/10.3390/cancers10100380

  2. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 2014;740:364-378.

    Article  CAS  Google Scholar 

  3. Francescato HDC, Almeida LF, Reis NG, Faleiros CM, Papoti M, Costa RS, Coimbra TM. Previous exercise effects in cisplatin-induced renal lesions in rats. Kidney Blood Press. Res. 2018;43(2):582-593.

    Article  CAS  Google Scholar 

  4. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J. Thromb. Haemost. 2007;5(12):2445-2452.

    Article  CAS  Google Scholar 

  5. Li W, Lam MS, Birkeland A, Riffel A, Montana L, Sullivan ME, Post JM. Cell-based assays for profiling activity and safety properties of cancer drugs.. J. Pharmacol. Toxicol. Methods. 2006;54(3):313-319.

    Article  CAS  Google Scholar 

  6. Nasser NJ, Fox J, Agbarya A. Potential mechanisms of cancerrelated hypercoagulability. Cancers (Basel). 2020;12(3). pii: E566. https://doi.org/10.3390/cancers12030566

  7. Oppelt P, Betbadal A, Nayak L. Approach to chemotherapyassociated thrombosis. Vasc. Med. 2015;20(2):153-161.

    Article  CAS  Google Scholar 

  8. Udut VV, Solov’еv MA, Karchagina OS, Borodulina EV, Tyutrin II, Klimenkova VF, Malyugin EF, Turenko AV. Global tests in evaluation of the function of pro and anticoagulant systems: Present and future. Bulletin of Experimental Biology and Medicine. 2015;159;(2):205-208.

    Article  CAS  Google Scholar 

  9. Xu Y, Ma H, Shao J, Wu J, Zhou L, Zhang Z, Wang Y, Huang Z, Ren J, Liu S, Chen X, Han J. A role for tubular necroptosis in cisplatin-induced AKI. J. Am. Soc. Nephrol. 2015;26(11):2647-2658.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. V. Filonova.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 170, No. 7, pp. 21-25, July, 2020

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Filonova, M.V., Fedorova, E.P., Churin, A.A. et al. Changes in Hemostasis System in Outbred Female Mice with Cisplatin-Induced Procoagulant Status. Bull Exp Biol Med 170, 15–18 (2020). https://doi.org/10.1007/s10517-020-04995-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-020-04995-3

Key Words

Navigation